Genmab A/S
GMAB
View Detailed Chart
26.050USD
+0.240+0.93%
Close 03/26, 16:00（ET）Quotes delayed by 15 min
16.05BMarket Cap
16.81P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.93%
5 Days
+0.77%
1 Month
-11.06%
6 Months
-9.67%
Year to Date
-15.42%
1 Year
+36.67%
View Detailed Chart
TradingKey Stock Score of Genmab A/S
Currency: USD Updated: 2026-03-25Key Insights
Genmab A/S's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 26 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 38.32.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Genmab A/S's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Genmab A/S Highlights
StrengthsRisks
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 55.58% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 3.72B.
Overvalued
The company’s latest PE is 16.85, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 65.54M shares, decreasing 13.04% quarter-over-quarter.
Held by Mairs and Power
Star Investor Mairs and Power holds 8.09K shares of this stock.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
38.318
Target Price
+49.21%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Genmab A/S News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Genmab A/S Info
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Ticker SymbolGMAB
CompanyGenmab A/S
CEOVan De Winkel (Jan G.J)
Websitehttps://www.genmab.com/
Related Instruments
-0.68%
-0.88%
+1.69%
-1.35%
+2.19%
+2.89%
+0.72%
+1.38%
-2.13%
+2.21%
-1.38%
+3.26%
+1.89%
+3.52%
+1.15%
0.00%
+2.01%
+0.28%
+0.62%
+0.03%Popular Symbols
252.980
+1.340 (+0.53%)
171.340
-3.860 (-2.20%)
69150.010
-1829.490 (-2.58%)
273.280
-27.770 (-9.22%)
2067.680
-96.310 (-4.45%)
372.260
-13.690 (-3.55%)
4389.090
-116.350 (-2.58%)
91.502
+0.563 (+0.62%)
1.154
-0.001 (-0.11%)
159.591
+0.132 (+0.08%)
